Drugs / VBC108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07700160 | Jul 2026 → Jul 2029 expected | cancer | VelaVigo Bio Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VBC108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07700160 ↗ |
| Modality | Monoclonal antibody | “CLDN18.2 and CDH17-directed Bi-specific Antibody Drug Conjugate” NCT07700160 ↗ |
| Target | CDH17 | “CLDN18.2 and CDH17-directed Bi-specific Antibody Drug Conjugate” NCT07700160 ↗ |